Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...

Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.

Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to ...

Technology can make that question easier to ask and answer, but for T1D patients, especially the kids who the disease ... which integrates easily into the Dexcom CGM ecosystem, seems an obvious ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients track their sugar levels constantly, allowing them to make better decisions for their health. DexCom's ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket ... This outlook considers sensor volume growth driven by increasing CGM access and awareness for people with diabetes, the continued rollout ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans for international growth suggest promising opportunities for future ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...